info@PremierEndpoint.com (914) 315-9334

The University of Texas MD Anderson Cancer Center and pharmaceutical giant Pfizer say they’ll jointly evaluate new combinations of three investigational immunotherapies and other agents to treat various solid tumors and blood cancers. The clinical agreement covers five studies, for now. An MD Anderson/Pfizer joint steering committee will oversee the initiative. Pfizer’s investigational therapies to […]

FALLS CHURCH, Va., Oct. 5, 2017 /PRNewswire-USNewswire/ — Inova Schar Cancer Institute announced today it is recruiting patients for the American Society of Clinical Oncology’s (ASCO) first-ever clinical trial, the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. The trial will evaluate molecularly targeted cancer drugs and collect data on clinical outcomes to learn about […]

SAN DIEGO, Oct. 5, 2017 /PRNewswire/ — Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that the U.S. Food and Drug Administration (FDA) has approved an 80 mg INGREZZA® (valbenazine) capsule strength to be used for the treatment of adults with tardive dyskinesia (TD). INGREZZA, a novel, selective vesicular monoamine transporter 2 (VMAT2) inhibitor, which was approved by […]

Tuebingen, Germany and Houston, Texas, October 4, 2017 – Immatics, a leading company in the field of cancer immunotherapy, today announced the completion of its Series E financing, raising $58 million. The Series E funding was supported by existing investors including dievini Hopp Biotech holding, Wellington Partners, AT Impf GmbH and others. This latest financing […]

HOUSTON, Oct. 3, 2017 /PRNewswire/ — ImmunoMet Therapeutics, a private biotechnology company focused on utilizing cellular metabolism to develop novel anti-tumor and immuno-oncology therapies, today announced that the Company has initiated its Phase 1 clinical study for IM156, a potent oxidative phosphorylation (OXPHOS) inhibitor. This is a dose escalation study designed to evaluate the safety […]

Ablynx scores with blood clot drug
October 2, 2017

Belgian biotech company Ablynx has received a boost with strong results from a late-stage trial into its experimental drug caplacizumab to treat a rare, life-threatening autoimmune blood clotting disorder. Acquired thrombotic thrombocytopenic purpura (aTTP) is caused by impaired activity of the ADAMTS13 enzyme and results in very low platelet count plus clot formation in small […]

Four months after two Endocyte drug candidates stumbled in early-stage studies, sparking a corporate shakeup, the company has signed a deal landing an experimental prostate cancer treatment that it says is ready for Phase 3 clinical trials. West Lafayette, IN-based Endocyte (NASDAQ: ECYT) says it paid $12 million up front to German biochemicals company ABX […]

1 2 3 37